Equillium Inc (EQ)

$0.49 -0.01 (-2.54%)
Market Cap 17.94M
Revenue (ttm) 41.10M
Net Income (ttm) -8.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -19.64%
Debt to Equity Ratio 0.00
Volume 134,700
Avg Vol 971,048
Day's Range N/A - N/A
Shares Out 35.61M
Stochastic %K 27%
Beta 1.87
Analysts Sell
Price Target $4.67

Latest News on EQ

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 11:16 AM EDT - 6 days ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 6 days ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 6 days ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 7 weeks ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 5 months ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 5 months ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 5 months ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 5 months ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 6 months ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 7 months ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 7 months ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 7 months ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 8 months ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 8 months ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 9 months ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to Participate in Upcoming Investor Conferences

Jul 2, 2024, 8:00 AM EDT - 9 months ago

Equillium to Participate in Upcoming Investor Conferences

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 10 months ago

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 10 months ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 11 months ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 11 months ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 11 months ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 11 months ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 1 year ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 1 year ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Nov 6, 2023, 8:00 AM EST - 1 year ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Equillium to Host Analyst & Investor Day

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Sep 20, 2023, 8:00 AM EDT - 1 year ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Aug 9, 2023, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces $7.5 Million Share Repurchase Program

Aug 2, 2023, 4:00 PM EDT - 1 year ago

Equillium Announces $7.5 Million Share Repurchase Program

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational Conferences

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

May 12, 2023, 4:15 PM EDT - 2 years ago

Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

May 11, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Mar 22, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Feb 17, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Feb 7, 2023, 8:00 AM EST - 2 years ago

Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Jan 13, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Dec 23, 2022, 4:01 PM EST - 2 years ago

Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Dec 16, 2022, 8:00 AM EST - 2 years ago

Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Dec 6, 2022, 7:00 AM EST - 2 years ago

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab